Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Wie begrijpt wat er aan de hand is? Het lijkt dat het Sopheon voor de wind gaat. Toch loopt de waarde van het aandeel sinds 2018 alleen maar achteruit.
Sopheon customers win three straight Outstanding Corporate Innovator Awards Forward-thinking companies have embraced the market trend of InnovationOps to operationalize their innovation efforts, reducing risk and increasing positive outcomes PITTSBURGH — September 6, 2023 — Sopheon, the InnovationOps software company, announced that its customers have won the Outstanding Corporate Innovator (OCI) Award for three consecutive years. These elite global corporations are recognized by the Product Development & Management Association (PDMA) for their innovation success. pdma-oci-logo-minIn its 36th year, the OCI Award is the only global innovation award that recognizes sustained and quantifiable business results from new products and services. The PDMA is a global community of professionals whose skills, expertise and experience power the most recognized and respected innovative companies in the world. The founding principle is that successful commercialization of products and innovation requires efficient cross-organizational processes from concept through end-of-life exit. “Sopheon is proud to work alongside many of the most innovative companies in the world,” said Greg Coticchia, CEO of Sopheon. “People often associate the word ‘innovation’ with young, start-up companies. But innovation is everywhere. A glance at the most successful long-term enterprises reveals innovation at every turn. Great companies are constantly redefining, reimagining and reinventing. The most recent winners of the Corporate Innovator Award are outstanding examples of companies that combine great vision and strategy with a world-class innovation management system.” Sopheon’s software offerings support InnovationOps thinking and principles that help organizations with managing discovery, product management, project management, portfolio management and governance. Sopheon enables a perfect combination of creativity and structure that allows companies to respond to market needs in real time. To experience the power of Sopheon’s InnovationOps software, visit Accolade®, Acclaim™ Ideas, Acclaim™ Projects and Acclaim™ Products. About Sopheon Sopheon (LON:SPE) empowers organizations to change the world while achieving exceptional long-term revenue growth and profitability. By operationalizing the entire innovation life cycle, Accolade® and Acclaim™ software and expertise enable innovation, product and project professionals to accomplish the full range of InnovationOps tasks to drive innovation at scale. Sopheon’s solutions have been implemented in over 50 countries by hundreds of blue-chip customers, including the three most recent winners of the PDMA’s Outstanding Corporate Innovator Award. Sopheon is listed on the AIM Market of the London Stock Exchange. Accolade® and Acclaim™ are trademarks of Sopheon plc.www.sopheon.com/about/press-releases/...
Sopheon sets new standard for InnovationOps Steady march of quarterly enhancements positions Accolade as leading choice for innovation and product professionals PITTSBURGH, Sept. 12, 2023 - Sopheon, the InnovationOps software company, announced the launch of Accolade 16.0, featuring improved collaboration capabilities, enhanced scenario planning and easier financial management through an expanded integration with Acclaim Projects. Accolade strengthens innovation and governance processes, and helps companies improve time-to-value. The release of Accolade 16.0 reflects Sopheon’s recognition of the growing industry adoption of InnovationOps, a holistic framework for operationalizing innovation from incremental to breakthrough across all areas of the company. Companies that embrace InnovationOps can effectively scale innovation for consistent and profitable growth. Accolade 16.0 highlights include: Expanded Acclaim Projects integration, which results in improved cost management. Managers can track the percentage of expenses that can be capitalized for better financial management. Additionally, project, schedule and financial health scores provide deeper insights into the status of innovation projects. Enhancements to scenario planning and prioritization that make it easier than ever to find and add any project to the Portfolio Planner. An improved workflow leads to greater efficiencies throughout the innovation process. Improved collaboration simplifies the process of connecting communication channels and enhances collaborative editing. New user interface simplifies resource and scenario planning. Accolade 16.0 enhances the look and feel of the interface for improvements when viewing available project resources. “In this version of Accolade, Sopheon has completely reimagined resource and capacity planning,” said Mike Bauer, chief product officer of Sopheon. “In addition to resulting in better product and portfolio decisions, these improvements help keep innovation programs heading in the proper strategic direction. Over the past year, Sopheon has made enormous strides in Accolade’s capabilities. Our commitment to regular quarterly updates is designed to ensure that Accolade continues to set the industry standard for enterprise innovation management.” Accolade is the industry’s most complete InnovationOps tool for managing strategy, governance and portfolios. It connects entire organizations and empowers product and innovation teams to be strategic and agile when responding to marketplace change and when delivering new products. The full transparency provided by Accolade makes it possible for companies to oversee governance, portfolio and strategy at an executive and leadership level, as well as manage products and projects at a team member level. To experience the power of Sopheon’s InnovationOps software, visit Accolade®, Acclaim™ Ideas, Acclaim™ Projects and Acclaim™ Productswww.sopheon.com/about/press-releases/...
Dank je, Gr Arie de Beuker
Spectator schreef op 10 september 2023 12:56 :
Wie begrijpt wat er aan de hand is? Het lijkt dat het Sopheon voor de wind gaat. Toch loopt de waarde van het aandeel sinds 2018 alleen maar achteruit.
Mogelijk dat beleggers eerst klinkende cijfers in omzet en winst willen zien. Nauwelijks handel in het aandeel helpt natuurlijk ook niet. Ik verwacht dat de omzet vanaf 2024 e.v. substantieel gaat stijgen
nog ff doorbijten, verwacht eind dit jaar, ruim 10 pond. komen ook nog 2 grote orders van 2 militaire bestaande klanten. volgens het verslag van 24 augustus 2023. volgend jaar kon het welis heel intresant gaan worden met soof. ligt er ook aan wat er allemaal in de wereld gaat gebeuren. time will tell.
Ik hoop dat jullie gelijk krijgen, Tritace en hunky. Ik vond een volledig tegengestelde mening hier: nl.investing.com/equities/sopheon
Beste Tritace en hunky, ik hoop ontzettend dat jullie gelijk krijgen. Een heel andere mening, helaas, vond ik hier: nl.investing.com/equities/sopheon
Volgens technische analyse zeggen ze verkopen maar de gezien de huidige ontwikkelingen, dus fundamenteel zou Sopheon best eens een mooie koopkans kunnen zijn. Gr Arie de Beuker
investing zegt verkopen , terwijl finn cap een target price van 12,50 pond blijft volhouden. je moet je eigen gevoel volgen, ik zit vol in soof. heb er genoeg koop niks meer bij, maar dit is wel een leuk koop prijsje. vorige maand heeft veradace partners nog voor rond de 2 miljoen euro aandelen gekocht. zouden ze dat in de blind hebben gedaan? ik denk zelf van niet. valt wel op dat de laatste tijd met een klein aantal de koers naar beneden wordt gedrukt. dat gebeurde ook in ik dacht in 2018, binnen een jaar stond de koers ruim op 14 pond. wat er ook gebeurt, ik hou ze stug vast. goed weekend all.
Ook ik zit flink in Soof, Hunkey. Hopelijk kunnen we Soofs goede resultaten een keer terugzien in de koers. Die kleine koersdrukkende dagelijkse aankopen blijf ik vreemd vinden.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
-0,10%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers